Xolair is a prescription medication that is used for the treatment of moderate to severe persistent asthma and chronic idiopathic urticaria (CIU), a condition characterized by hives and itching that occurs for unknown reasons. The active ingredient in Xolair is omalizumab, which belongs to a class of drugs known as monoclonal antibodies.
Xolair works by targeting and blocking a specific type of antibody, called immunoglobulin E (IgE). IgE is responsible for triggering allergic reactions in the body, such as asthma and hives. By binding to IgE, Xolair helps to prevent it from attaching to cells in the body, limiting the release of chemicals that cause the symptoms of asthma and CIU.
Xolair is typically administered by injection under the skin. The dosage and frequency of administration may vary depending on the individual's condition and response to treatment. It is usually recommended for individuals who have not adequately responded to other asthma medications or antihistamines for CIU.
As with any medication, Xolair may cause side effects. Common side effects may include injection site reactions, such as pain, redness, or itching. Other potential side effects may include headache, joint pain, fatigue, and upper respiratory tract infections. Rare but serious allergic reactions have also been reported with the use of Xolair.
It is important to consult with a healthcare professional before starting Xolair to determine if it is the appropriate treatment option for asthma or CIU.
Overall, Xolair is a medication that works by blocking a specific antibody to control symptoms of asthma and chronic idiopathic urticaria.
